Pembrolizumab was recently approved for use in the first-line setting for metastatic nonsquamous NSCLC in combination with pemetrexed and carboplatin independent of PDL1 expression4, or as a second-line single agent for patients with PDL1 expression levels of 1% or more5. The gene discussed is CD274; the disease is non-small cell lung carcinoma.